Latest News and Press Releases
Want to stay updated on the latest news?
-
REDWOOD CITY, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced that new data comparing the anti-tumor immune response of its anti-DLL4/VEGF bispecific...
-
OncoMed Pharmaceuticals to Report Third Quarter 2015 Financial Results on Thursday, November 5, 2015
REDWOOD CITY, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology...
-
REDWOOD CITY, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced that data related to three of its clinical-stage programs will be presented at the...
-
REDWOOD CITY, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...
-
NEW YORK and REDWOOD CITY, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
-
New Prognostic and Prevalence Data Highlight Role of Notch3 Overexpression in Small Cell Lung Cancer Encouraging Efficacy Results Updated from Phase 1b Clinical Trial of Tarextumab DENVER,...
-
REDWOOD CITY, Calif., Aug. 31, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics,...
-
REDWOOD CITY, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) -- New biomarker data related to OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Phase 1b/2 PINNACLE clinical trial of tarextumab (Anti-Notch 2/3,...
-
REDWOOD CITY, Calif., Aug. 10, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED) today reported financial results for the quarter ended June 30, 2015 and provided an update on...
-
REDWOOD CITY, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology therapeutics,...